Clinical profile, risk factors, disease severity, and outcome for COVID-19 disease in patients with tuberculosis on treatment under the National Tuberculosis Elimination Program: a cohort of 1400 patients

Submitted: June 26, 2024
Accepted: September 19, 2024
Published: November 8, 2024
Abstract Views: 275
PDF_EARLY VIEW: 51
SUPPLEMENTARY MATERIAL: 4
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

COVID-19 affected millions of people worldwide, and tuberculosis (TB) continues to affect millions of people each year. The combined pandemic of COVID-19 and TB had a catastrophic effect on healthcare policies and healthcare setups around the globe. The clinical profile and factors affecting the outcome of COVID-19 disease in TB patients on treatment in field conditions have not been studied in detail. The present study attempted to study the occurrence of COVID-19 among patients on TB treatment in terms of severity of COVID-19 disease and outcome of both COVID-19 and TB in patients at National Tuberculosis Elimination Program treatment centers over a period of one year during peak COVID-19 times. Out of 1400 TB patients enrolled, 65 (5%) suffered from COVID-19 disease. Of the 65 TB patients with COVID-19 disease, 37 (57%) were male and under 45 years old, 33 (51%) had a TB diagnosis after first receiving a COVID-19 diagnosis, 29 (45%) had a TB diagnosis first, and received anti-TB treatment before receiving a COVID-19 diagnosis, and only 3 patients (5%) had a COVID-19 and TB diagnosis concurrently. The majority of 59 (91%) patients had mild COVID-19 disease. The outcome of TB treatment was available in 25 patients out of these 65 COVID-19-positive patients, with 21 (84%) patients having a favorable outcome. Out of the 65 COVID-19-positive patients, 4/25 (16%) had unfavorable outcomes, with one patient (4%) failing TB treatment and two patients (8%) dying. This is the first study from India that studied the occurrence and course of COVID-19 among a large number of TB patients taking anti-TB treatment under programmatic conditions. Due to the similarity in symptoms of TB and certain viral respiratory illnesses, a protocol should be established for health care to check patients for both illnesses.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 co-infection: description of the global cohort. Eur Respir J 2022;59:2102538. DOI: https://doi.org/10.1183/13993003.02538-2021
McQuaid CF, Vassall A, Cohen T, et al. The impact of COVID-19 on TB: a review of the data. Int J Tuberc Lung Dis 2021;25:436-46. DOI: https://doi.org/10.5588/ijtld.21.0148
Mousquer GT, Peres A, Fiegenbaum M. Pathology of TB/COVID-19 co-infection: the phantom menace. Tuberculosis 2021;126:102020. DOI: https://doi.org/10.1016/j.tube.2020.102020
Tadolini M, Codecasa LR, García-García JM, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J 2020;56:2001398. DOI: https://doi.org/10.1183/13993003.01398-2020
Motta I, Centis R, D’Ambrosio L, et al. Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology 2020;26:233-40. DOI: https://doi.org/10.1016/j.pulmoe.2020.05.002
Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, South Africa. Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape province, South Africa. Clin Infect Dis 2021;73:e2005-15.
Sy KTL, Haw NJL, Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infectious Dis 2020;52:902-7. DOI: https://doi.org/10.1080/23744235.2020.1806353
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33. DOI: https://doi.org/10.1056/NEJMoa2001017
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20. DOI: https://doi.org/10.1056/NEJMoa2002032
Gupta N, Agrawal S, Ish P, et al. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India. Monaldi Arch Chest Dis 2020;90:1294. DOI: https://doi.org/10.4081/monaldi.2020.1294
Ong CWM, Migliori GB, Raviglione M, et al. Epidemic and pandemic viral infections: impact on tuberculosis and the lung: a consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J 2020;56:2001727. DOI: https://doi.org/10.1183/13993003.01727-2020
WHO. WHO COVID-19 dashboard. Available from: https://covid19.who.int/table.
Gupta N, Ish P, Gupta A, et al. A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis. Eur Respir J 2020;56:2003408. DOI: https://doi.org/10.1183/13993003.03408-2020
Song WM, Zhao JY, Zhang QY, et al. COVID-19 and tuberculosis coinfection: an overview of case reports/case series and meta-analysis. Front Med 2021;8:657006. DOI: https://doi.org/10.3389/fmed.2021.657006
Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A 2020;117:17720-6. DOI: https://doi.org/10.1073/pnas.2008410117

Ethics Approval

Research and ethical approval (office letter no. NITRD/RC/2021/6291, letter no. NITRD/EC/2021/6831 respectively) were obtained from Institutional Research and Ethical Committee.

How to Cite

Singla, Neeta, Amitesh Gupta, U.K. Khalid, Ravindra Kumar Dewan, and Rupak Singla. 2024. “Clinical Profile, Risk Factors, Disease Severity, and Outcome for COVID-19 Disease in Patients With Tuberculosis on Treatment under the National Tuberculosis Elimination Program: A Cohort of 1400 Patients”. Monaldi Archives for Chest Disease, November. https://doi.org/10.4081/monaldi.2024.3103.

Similar Articles

<< < 1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.